Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Azitra Inc AZTR

Healthcare Biotechnology
Azitra, Inc. is an early-stage clinical biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics... see more

Recent & Breaking News (NYSEAM:AZTR)

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Business Wire 11 hours ago

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire 12 days ago

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Business Wire August 28, 2024

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Business Wire August 22, 2024

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Business Wire August 20, 2024

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Business Wire August 12, 2024

Azitra, Inc. Announces Closing of Public Offering

Business Wire July 25, 2024

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Business Wire July 23, 2024

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

Business Wire July 23, 2024

Azitra, Inc. Announces Reverse Stock Split

Business Wire June 27, 2024

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Business Wire May 31, 2024

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

Business Wire May 17, 2024

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

Business Wire May 10, 2024

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Business Wire May 9, 2024

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Business Wire April 22, 2024

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

Business Wire April 18, 2024

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Business Wire March 15, 2024

Azitra, Inc. Announces Closing of Public Offering

Business Wire February 16, 2024

Azitra, Inc. Announces Pricing of Public Offering

Business Wire February 13, 2024

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Business Wire January 16, 2024